ABSTRACT
V. S. ROGOVSKY, T. M. ARZAMASOVA, M. A. ROSENFELD, M. L. KONSTANTINOVA, V. B. LEONOVA, S. D. RAZUMOVSKY, G. E. ZAIKOV, A. I. MATYOUSHIN, N. L. SHIMANOVSKY, A. M. KOROTEEV, S. E. MOSYUROV, M. P. KOROTEEV, T. S. KUHAREVA, and E. E. NIFANTIEV
10.1 Introduction ................................................................................ 164 10.2 Experimental .............................................................................. 166 10.3 Results and Discussion .............................................................. 168 10.4 Conclusion ................................................................................. 172 Keywords .............................................................................................. 173 References ............................................................................................. 173
10.1 INTRODUCTION
Dihydroquercetin (taxifolin, DHQ) is a natural flavonoid, which possesses antioxidant activity and other pharmacological properties (anti-inflammatory, anti-atherosclerotic, etc.). Dihydroquercetin is hydrophobic compound, that’s why it can’t be administered intravenously, also its oral bioavailability is reduced. Recently, many new dihydroquercetin derivatives were synthesized, including water-soluble forms (cyclodextrin inclusion complexes with dihydroquercetin derivatives). In addition to the protective effect of antioxidants against lipid peroxidation, increasing attention is paid to the possibilities of antioxidants including dihydroquercetin to prevent an oxidation of proteins. Fibrinogen is more susceptible to oxidation than most other plasma proteins.
